Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development

Cancer Research

Volumn 69, Issue 2, 2009, Pages 678-686

  Zeng, Qinghua ^a   Phukan, Sharbani ^b   Xu, Yanfei ^b   Sadim, Maureen ^b   Rosman, Diana S ^b   Pennison, Michael ^a   Liao, Jie ^b   Yang, Guang Yu ^b   Huang, Chiang Ching ^b   Valle, Laura ^c   Di Cristofano, Antonio ^d   De La Chapelle, Albert ^c   Pasche, Boris ^a,e  

^a University of Alabama at Birmingham   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CYCLIN D1; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; COLON ADENOCARCINOMA; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTESTINE TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL GROWTH PROCESSES; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEMATOPOIESIS; INBREEDING; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 58349120416     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3980     Document Type: Article

References (42)

1. Howe JR, Sayed MG, Ahmed AF, et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet 2004;41:484-91.
2. Broderick P, Carvajal-Carmona L, Pittman AM, et al. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet 2007;39:1315-7.
3. Xie W, Rimm DL, Lin Y, Shih WJ, Reiss M. Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J 2003;9:302-12.
4. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.
5. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. Intestinal tumorigenesis in compound mutant mice of both dpc4 (Smad4) And apc genes. Cell 1998;92:645-56.
6. Munoz NM, Upton M, Rojas A, et al. Transforming growth factor β receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 2006;66:9837-44.
7. Min/+ mice. Cancer Res 2006;66:8430-8.
8. Kim BG, Li C, Qiao W, et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 2006;441:1015-9.
9. Hohenstein P, Molenaar L, Elsinga J, et al. Serrated adenomas and mixed polyposis caused by a splice acceptor deletion in the mouse Smad4 gene. Genes Chromosomes Cancer 2003;36:273-82.
10. Taketo MM, Takaku K. Gastro-intestinal tumorigenesis in Smad4 mutant mice. Cytokine Growth Factor Rev 2000;11:147-57.
11. Alberici P, Jagmohan-Changur S, de PE, et al. Smad4 haploinsufficiency in mouse models for intestinal cancer. Oncogene 2006;25:1841-51.
12. Pasche B, Luo Y, Rao PH, et al. Type I transforming growth factor β receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res 1998;58:2727-32.
13. Chen T, de Vries EG, Hollema H, et al. Structural alterations of transforming growth factor-β receptor genes in human cervical carcinoma. Int J Cancer 1999;82:43-51.
14. Pasche B, Kolachana P, Nafa K, et al. TβR-I(6A) is a candidate tumor susceptibility allele. Cancer Res 1999;59:5678-82.
15. Bian Y, Caldes T, Wijnen J, et al. TGFBR1*6A may contribute to hereditary colorectal cancer. J Clin Oncol 2005;23:3074-8.
16. Xu Y, Pasche B. TGF-β signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet 2007;16 Spec No 1:R14-20.
17. Kaklamani VG, Baddi L, Liu J, et al. Combined genetic assessment of transforming growth factor-β signaling pathway variants may predict breast cancer risk. Cancer Res 2005;65:3454-61.
18. Valle L, Serena-Acedo T, Liyanarachchi S, et al. Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science 2008;321:1361-5.
19. Hogan B, Beddington R, Costantini F, Lacy E. Manipulating the mouse embryo. 2nd ed. Cold Spring Harbor Laboratory Press; 1994.
20. Tsutsui T, Hesabi B, Moons DS, et al. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol 1999;19:7011-9.
21. Pasche B, Knobloch TJ, Bian Y, et al. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA 2005;294:1634-46.
22. Rosman DS, Phukan S, Huang CC, Pasche B. TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation. Cancer Res 2008;68:1319-28.
23. Larsson J, Goumans MJ, Sjostrand LJ, et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. EMBO Journal 2001;20:1663-73.
24. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-4.
25. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668-70.
26. Carcamo J, Zentella A, Massague J. Disruption of transforming growth factor β signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol Cell Biol 1995;15:1573-81.
27. Zawel L, Dai JL, Buckhaults P, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998;1:611-7.
28. Dong M, Blobe GC. Role of transforming growth factor-β in hematologic malignancies. Blood 2006;107:4589-96.
29. Becker C, Fantini MC, Schramm C, et al. TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491-501.
30. Liu XD, Sun Y, Constantinescu SN, Karam E, Weinberg RA, Lodish HF. Transforming growth factor β-induced phosphorylation of smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc 1997;94:10669-74.
31. Zhu YA, Richardson JA, Parada LF, Graff JM. Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998;94:703-14.
32. 2-terminal kinase during human colorectal carcinogenesis. Cancer Res 2005;65:157-65.
33. Matsuzaki K. Smad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis. Histol Histopathol 2006;21:645-62.
34. Min mice. Mol Cell Biol 2004;24:7598-611.
35. van de WM, Sancho E, Verweij C, et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002;111:241-50.
36. Hinoi T, Akyol A, Theisen BK, et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 2007;67:9721-30.
37. Boivin G, Washington K, Yang K, et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003;124:762-77.
38. + myeloid cells that promote invasion. Nat Genet 2007;39:467-75.
39. Massague J. G1 cell-cycle control and cancer. Nature 2004;432:298-306.
40. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003;3:807-20.
41. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589-600.
42. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science 1998;280:1036-7.